Ablation

NeuroOne Reports First Quarter Fiscal Year 2022 Financial Results and Provides Corporate Update

Retrieved on: 
Monday, February 14, 2022
NASDAQ, Patient, CEO, Company, Zimmer Biomet, Calendar, AES, Ablation, Commercial, American Epilepsy Society, Lists of diseases, Evo, FDA, Ageing, EDEN, NMTC, Seeg, Electrode, Medical device, Coal

Dave Rosa, CEO of NeuroOne commented, "During and subsequent to our fiscal first quarter, we made significant advancements across our product portfolio.

Key Points: 
  • Dave Rosa, CEO of NeuroOne commented, "During and subsequent to our fiscal first quarter, we made significant advancements across our product portfolio.
  • R&D expense in the first quarter of fiscal 2022 was$1.1 million, compared with$0.9 million in the same period of fiscal 2021.
  • SG&A expense in the first quarter of fiscal 2022 was$1.7 million, compared with$1.2 million in the prior year period.
  • Net loss was$2.8 millionfor the first quarter of fiscal 2022, compared to a net loss of$2.0 million in the first quarter of fiscal 2021.

Cabaletta Bio Strengthens Executive Leadership Team with Promotions of Gwendolyn Binder, Ph.D. to President of Science and Technology and Arun Das, M.D. to Chief Business Officer

Retrieved on: 
Tuesday, January 11, 2022
HIV, Annual report, University, Private Securities Litigation Reform Act, Public health, Lymphocyte, U.S. Securities and Exchange Commission, Industry, CD19, Coronavirus Scientific Advisory Board (Turkey), Mike Hopkins (basketball), Cancer, Investigational New Drug, Business development, Human, Publication, Clinical trial, Molecular medicine, Form 10-K, Safety, MuSK protein, Ablation, Gene editing, Food, Pemphigus, FDA, Patient, Science and technology, Johns Hopkins University, Pemphigus vulgaris, MPV, Leadership, Health, Regulation of tobacco by the U.S. Food and Drug Administration, Technology, Neoplasm, Bureau of Oceans and International Environmental and Scientific Affairs, GLOBE, IND, Translation, Risk, TCR, Goldman Sachs, Security (finance), Board, Johns Hopkins School of Medicine, Pharmaceutical industry, Science, Novartis, COVID-19, Cabaletta

In these new roles, Dr. Binder and Dr. Das will continue to report to Steven Nichtberger, M.D., Chief Executive Officer and Co-founder of Cabaletta.

Key Points: 
  • In these new roles, Dr. Binder and Dr. Das will continue to report to Steven Nichtberger, M.D., Chief Executive Officer and Co-founder of Cabaletta.
  • In her elevated position as President of Science and Technology, with the recently announced promotions of our Chief Scientific Officer and Chief Compliance Officer, we look forward to leveraging her expertise for broader strategic insight and leadership.
  • Arun has made key strategic contributions to the business, including establishing many of the collaborations in our network of academic and industry partners.
  • Dr. Binder was one of Cabalettas first employees, joining in February 2019, and was most recently Executive Vice President of Science and Technology.

Cabaletta Bio to Present at the 40th Annual J.P. Morgan Healthcare Conference

Retrieved on: 
Monday, January 10, 2022
Health, Clinical trial, MuSK protein, Patient, Conference, Ablation, Food, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, News, FDA, Webcast, GLOBE, Pemphigus, Pharmaceutical industry

PHILADELPHIA, Jan. 10, 2022 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases, today announced that Steven Nichtberger, M.D., President and Chief Executive Officer, will present at the 40th Annual J.P. Morgan Healthcare Conference on Wednesday, January 12, 2022 at 9:00 a.m.

Key Points: 
  • PHILADELPHIA, Jan. 10, 2022 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases, today announced that Steven Nichtberger, M.D., President and Chief Executive Officer, will present at the 40th Annual J.P. Morgan Healthcare Conference on Wednesday, January 12, 2022 at 9:00 a.m.
  • A live webcast of the presentation will be available on the News and Events section of the companys website at www.cabalettabio.com .
  • Following the presentation, a replay of the webcast will be available on the website for 90 days.
  • For more information about the DesCAARTes Phase 1 clinical trial, please visit our website ( DesCAARTes Phase 1 Trial ).

Cabaletta Bio to Present at the H.C. Wainwright BioConnect Conference

Retrieved on: 
Monday, January 3, 2022
Ablation, Pemphigus, Clinical trial, FDA, Health, GLOBE, Food, Conference, Patient, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, News, MuSK protein, Pharmaceutical industry

The pre-recorded presentation will be available on the News and Events section of the companys website at www.cabalettabio.com .

Key Points: 
  • The pre-recorded presentation will be available on the News and Events section of the companys website at www.cabalettabio.com .
  • Replays of the presentation will be available on the website for 90 days.
  • For more information about the DesCAARTes Phase 1 clinical trial, please visit our website ( DesCAARTes Phase 1 Trial ).
  • The Companys MuSK-CAART product candidate is designed as a potential treatment for patients with MuSK-associated myasthenia gravis.

Cabaletta Bio Reports Top-line Biologic Activity Data from Two Lowest Dose Cohorts in DesCAARTes™ Trial in Patients with Mucosal Pemphigus Vulgaris

Retrieved on: 
Tuesday, December 14, 2021
U.S. Securities and Exchange Commission, MuSK protein, Food, FDA, Pemphigus vulgaris, Protein, Health, Clinical trial, Cell, Immunity, A3, Public health, Private Securities Litigation Reform Act, Ablation, Autoimmunity, Autoantibody, Risk, Annual report, Form 10-K, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Pemphigus, Safety, Goal, Patient, Desmoglein-1, Disease, DSG1, Security (finance), Infection, Observation, Political movement, Patient safety, GLOBE, A2, CAR, Skin, Pharmaceutical industry, Medical device, Risk management, Vaccine, IND, COVID-19, MPV, Cabaletta, DSG3

The systemic therapies may have impacted clinical scores and DSG3 levels, both of which improved between screening and infusion.

Key Points: 
  • The systemic therapies may have impacted clinical scores and DSG3 levels, both of which improved between screening and infusion.
  • Additional data on the initial cohorts in the DesCAARTes trial are anticipated to be presented at medical meetings and/or scientific sessions in 2022.
  • Cabalettas DesCAARTes Phase 1 trial is an open-label, multi-center study of DSG3-CAART in adults with mucosal-dominant pemphigus vulgaris (mPV).
  • For more information about the DesCAARTes Phase 1 clinical trial, please visit our website ( DesCAARTes Phase 1 Trial ).

The Worldwide Pain Management Devices Industry is Expected to Reach $3.3 Billion by 2026 - ResearchAndMarkets.com

Retrieved on: 
Friday, November 19, 2021
Medical Devices, Health, Patient, Asia, Ageing, Adoption, Pain, Peripheral neuropathy, Brain, Population, CAGR, Pain management, USD, Pump, Cancer pain, Lists of diseases, Ablation, MSK, Nature, SCS, Spinal cord, Chronic pain, NA, Quality of life, Neuropathic pain, Incidence, OTC, Region, Pain scale, TENS, Growth, Medical device, Dentistry

Based on type, the pain management devices market is segmented into neurostimulation devices, infusion pumps, and ablation devices.

Key Points: 
  • Based on type, the pain management devices market is segmented into neurostimulation devices, infusion pumps, and ablation devices.
  • Based on application, the pain management devices market is segmented into neuropathic pain, musculoskeletal pain, cancer pain, facial pain & migraine, and other applications.
  • The presence of substantial clinical evidences in the favor of high efficacy of pain management devices in neuropathic pain treatment, development of novel neuropathic pain management devices, rising aging population across the globe (geriatric population is at high risk of neuropathic pain due to the increased incidence of neuropathic pain associated with many age-related diseases), side effects of drugs used to treat neuropathic pain, and availability of reimbursement are fueling the adoption of pain management devices for neuropathic pain treatment are the major factors contributing to the growth of the pain management devices market for neuropathic pain applications.
  • The pain management devices market in the US is expected to offer growth opportunities in the coming years owing to the increasing adoption of pain management devices in ambulatory care centers.

Cabaletta Bio to Participate in Upcoming Investor Conferences in November

Retrieved on: 
Tuesday, November 9, 2021
Health, Clinical trial, News, Ablation, Pemphigus, Conference, Company, GLOBE, Guggenheim, MuSK protein, Patient, FDA, Pharmaceutical industry

Members of management will also be available for one-on-one meetings.

Key Points: 
  • Members of management will also be available for one-on-one meetings.
  • Evercore ISI 4th Annual HealthCONx Conference: Steven Nichtberger, M.D., President and Chief Executive Officer, will participate in a fireside chat on Tuesday, November 30, 2021 at 12:35 p.m.
  • Both presentations will be available on the News and Events section of the companys website at www.cabalettabio.com .
  • For more information about the DesCAARTes Phase 1 clinical trial, please visit our website ( DesCAARTes Phase 1 Trial ).

Cabaletta Bio Expands Executive Leadership Team with Appointments of Samik Basu, M.D. to Chief Scientific Officer and Heather Harte-Hall, MSc. to Chief Compliance Officer

Retrieved on: 
Tuesday, November 9, 2021
Industry, Autoimmunity, Clinical trial, Security (finance), National, Regenerative medicine, Growth, CSO, Annual report, University, Laboratory, Business administration, Pfizer, Risk, Safety, Form 10-K, Clinical and Translational Science, Culture, Leadership, Temple University, MPV, Technology, Research, Risk management, U.S. Securities and Exchange Commission, GLOBE, SCCE, Saint Leo University, Albert Einstein College of Medicine, MuSK protein, Patient, FDA, Compliance, Private Securities Litigation Reform Act, Health, Clinical pathology, Society, Pembrolizumab, Ablation, Capella University, LLC, Pemphigus vulgaris, Translational medicine, Merck & Co., Public health, ARM, Pemphigus, CCO, Degenerative disease, Quality, Pharmaceutical industry, Vaccine

to Chief Scientific Officer (CSO) and Heather Harte-Hall to Chief Compliance Officer (CCO).

Key Points: 
  • to Chief Scientific Officer (CSO) and Heather Harte-Hall to Chief Compliance Officer (CCO).
  • Samik and Heather are both highly respected and accomplished leaders at Cabaletta and we are thrilled to announce their well-deserved promotions to these new roles.
  • Dr. Basu joined Cabaletta in December 2019 and was most recently Vice President of Preclinical Research and Translational Medicine before assuming his new role as Chief Scientific Officer.
  • Ms. Harte-Hall joined Cabaletta in March 2019 and was most recently Vice President of Quality and Compliance before assuming her new role as Chief Compliance Officer.

Hologic to Launch the NovaSure® V5 Global Endometrial Ablation Device at Upcoming American Association of Gynecologic Laparoscopists 50th Global Congress

Retrieved on: 
Tuesday, November 2, 2021
Medical Devices, Health, Consumer, Surgery, Women, Biotechnology, Woman, Infection, MD, Fractionation Research Inc., V5, Association, Faecal calprotectin, Â, Menstrual disorder, Partnership, IFU, Patient, FDA, ISBN, Cramp, Suction, Ablation, Nausea, Congress, Anatomy, Vomiting, Physician, Pregnancy, Perforation, Use, Multimedia, HOLX, Gold, Health, Nasdaq, Research, American Association, AAGL, Science, Gynecological surgery, GEA, Pharmaceutical industry, Medical imaging, Birth control

Hologic, Inc. (Nasdaq: HOLX), a global leader in women's health, will launch the NovaSure V5 global endometrial ablation (GEA) device at the American Association of Gynecologic Laparoscopists (AAGL) 50th Global Congress on (November 14-17).

Key Points: 
  • Hologic, Inc. (Nasdaq: HOLX), a global leader in women's health, will launch the NovaSure V5 global endometrial ablation (GEA) device at the American Association of Gynecologic Laparoscopists (AAGL) 50th Global Congress on (November 14-17).
  • The most studied and trusted endometrial ablation procedure in the United States, the innovative new NovaSure V5 device represents Hologic's ongoing commitment to enhance the physician experience.1
    This press release features multimedia.
  • Guided by womens unique needs and the physicians that treat them, the NovaSure V5 device features several innovations, making it the most sophisticated device in the NovaSure family.
  • The NovaSure V5 device will be on display at the Hologic booth #536 and online at Hologics virtual surgery suite ( https://hologic.protoexpo.com/surgical/ ).

Cabaletta Bio Reports Third Quarter 2021 Financial Results and Provides Business Update

Retrieved on: 
Monday, November 1, 2021
Safety, Spark Therapeutics, Facility, U.S. Securities and Exchange Commission, ASN, Clinical trial, COVID-19, Program, Health, ATM, Food and Drug Administration, GLOBE, MPV, Wuxi, Research, Ablation, Security (finance), Private Securities Litigation Reform Act, University of Pennsylvania, Investigational New Drug, Company, Investment, Supply chain, Â, Business development, Industry, Real estate, Guggenheim, Wharton School of the University of Pennsylvania, GMP, Risk, MuSK protein, American Society of Nephrology, Pemphigus, Growth, Society, Technology, University, Annual report, Myasthenia gravis, Patient, Change request, FDA, Conference, Penn, Form 10-K, Coronavirus Scientific Advisory Board (Turkey), Infrared spectroscopy correlation table, Vaccine, Pharmaceutical industry, Animal

The Company remains on track to submit an IND to the FDA in the fourth quarter of 2021.

Key Points: 
  • The Company remains on track to submit an IND to the FDA in the fourth quarter of 2021.
  • PLA2R-CAART advancing toward clinical development: Cabaletta expects to conduct a pre-IND interaction with the FDA in the fourth quarter of 2021.
  • Dr. Payne is a University of Pennsylvania (Penn) faculty member, scientific collaborator, key advisor, and co-founder of Cabaletta Bio.
  • The University of Pennsylvania may also receive future financial benefit under licenses it has granted to Cabaletta Bio.